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Objectives: We sought to evaluate the long-term results of mitral valve repair in
patients with mitral regurgitation caused by floppy mitral valves and compare the
outcomes of asymptomatic patients with those of symptomatic patients.
Methods: A retrospective review of 488 consecutive patients who had mitral valve
repair for floppy mitral valve disclosed 199 patients who were asymptomatic or had
minimal symptoms and 289 patients who were symptomatic at the time of the
operation. Asymptomatic patients were younger, had better ventricular function, had
a lower incidence of coronary artery disease, and had higher rates of atrial fibril-
lation than symptomatic patients.
Results: Survival at 15 years was 61% for all patients. Survival was 76% for
asymptomatic patients, which was identical to that for the general population
matched for age and sex, whereas the survival of symptomatic patients was 53% and
significantly lower than that of the general population. Cox regression analyses
validated by means of bootstrap methodology identified the following predictors of
late death: age by increments of 5 years (risk ratio  1.2), New York Heart
Association functional classes 3 and 4 (risk ratio  3.0), left ventricular ejection
fraction of less than 40% (risk ratio 2.7), preoperative stroke or transient ischemic
attack (risk ratio  3.1), previous cardiac operation (risk ratio  4.6), and severe
chronic obstructive pulmonary disease (risk ratio  3.1). Freedom from reoperation
at 15 years was 91%, and it was similar for asymptomatic and symptomatic patients.
Freedom from mitral regurgitation of greater than 2 at 15 years was 85% for all
patients, 96% for asymptomatic patients, and 76% for symptomatic patients.
Conclusions: This study supports the recommendation of surgical intervention in
asymptomatic patients with mitral regurgitation caused by a floppy mitral valve if mitral
valve repair is feasible and associated with low operative mortality and morbidity.
Floppy mitral valves are very common. In the Framingham Heart Studythey were found in 2.5% of men and 7.6% of women by means ofM-mode echocardiography.1 In a large autopsy study by Davies andassociates,2 the frequency was 3.9% in men and 5.2% in women.Mitral regurgitation (MR) is an uncommon complication of a floppymitral valve,1,2 but because this entity is very prevalent, MR as a result
of mitral valve prolapse is the most common cause of MR in North America.3
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The onset of MR in patients with floppy mitral valves is
often insidious, and symptoms might not occur until the left
ventricle fails. In the past, the indication for surgical inter-
vention was based on the burden of symptoms versus the
risk and uncertainties of mitral valve replacement. At
present, surgical intervention is recommended in asymp-
tomatic patients with severe MR to prevent left ventricular
dysfunction as long as the mitral valve can be repaired with
low operative mortality.4,5
This study is an analysis of the clinical and echocardio-
graphic outcomes of mitral valve repair for MR caused by
floppy mitral valves in patients with and without symptoms.
Patients and Methods
From 1981 to 1998, 612 patients with MR caused by floppy mitral
valves underwent mitral valve surgery performed by one surgeon.
Mitral valve repair was performed in 488 (80%) patients, and
mitral valve replacement was performed in 124 (20%) patients.
The ratio between mitral valve repair and mitral valve replacement
for mitral valve prolapse increased from 25% in 1981 to 90% to
95% after 1990.
Patients were divided into 2 groups: asymptomatic and mini-
mally symptomatic patients (New York Heart Association
[NYHA] functional classes 1 and 2) and symptomatic patients
(NYHA functional classes 3 and 4). In the first group 55 patients
had no symptoms of heart disease, and 144 had minimal symp-
toms, and in the second group 212 were in functional class 3, and
77 were in functional class 4. Table 1 shows the clinical profile of
all patients, as well as the clinical profiles of the 2 groups. Most
asymptomatic patients (NYHA functional class 1) were operated
on because of impaired left ventricular systolic function or aortic
root aneurysm.
Most operations were performed electively, but 69 patients
required urgent surgical intervention because of intractable con-
gestive heart failure, active infective endocarditis, or both.
Operative Procedures
The techniques of mitral valve repair used in this series were
basically those described by Carpentier,6 but certain modifications
TABLE 1. Clinical profile of patients with and without symptoms
All patients Asymptomatic Symptomatic P value
No. of patients 488 199 289
Age, mean  SD (y) 58 13 54 14 61 12 .01
Male sex 347 (71) 150 (75) 197 (68) .08
Medical history
Congestive heart failure 318 (65) 61 (31) 257 (89) .0001
Stroke/TIA 31 (6) 9 (4) 22 (8) .17
Hypertension 125 (26) 37 (19) 88 (30) .003
Renal failure (dialysis) 4 1 3 .51
COPD (FEV1 1.0) 15 (3) 0 15 (5) .001
Diabetes mellitus 19 (4) 4 (2) 15 (5) .07
Endocarditis
Healed 40 (9) 23 (11) 24 (8) .41
Active 3 1 3
Marfan syndrome 7 6 1 .17
Previous heart operations 10 5 5 .54
Aortic valve replacement 2 0 2
Mitral valve repair 4 3 1
Atrial septal defect 2 1 1
Coronary artery bypass 2 1 1
Electrocardiogram
Sinus rhythm 344 (70) 175 (88) 169 (59)
Atrial fibrillation 140 (29) 23 (11) 117 (40) .0001
Heart block/pacemaker 4 1 3
Associated cardiac diseases
Aortic root/ascending aneurysm 13 (3) 8 (4) 5 (2) .12
Aortic valve disease 38 (8) 19 (10) 19 (7) .22
Tricuspid valve disease 15 (3) 2 (1) 13 (4) .028
Coronary artery disease 81 (17) 22 (11) 59 (20) .006
HOCM 5 0 5 (2) .06
Left ventricular ejection fraction
 60% 230 (47) 125 (63) 105 (36)
41%-59% 228 (47) 70 (35) 158 (55)
21%-40% 28 (6) 4 (2) 24 (8)
20% 2 0 2 .0001
Percentages are shown in parentheses. P values are for the differences between asymptomatic and symptomatic groups. COPD, Chronic obstructive
pulmonary disease; FEV1, forced expiratory volume in 1 second; HOCM, hypertrophic obstructive cardiomyopathy.
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were introduced over the years. The first was the use of expanded
polytetrafluoroethylene (ePTFE) sutures to reinforce or replace
chordae tendineae in 1985.7 Another change was the method of
resection of the central scallop of the posterior leaflet. Quadran-
gular or rectangular resection of the posterior leaflet with plication
of the mitral annulus was replaced by a more triangular resection
with detachment of a portion of the posterior leaflet from the mitral
annulus and sliding plasty to prevent kinking or damage of a
dominant circumflex artery and to reduce the risk of systolic
anterior motion of the anterior leaflet.8,9 Finally, the annuloplasty
ring was first changed from a rigid to a flexible ring and then to a
posterior band. A few patients with horseshoe calcification of the
mitral annulus had mitral valve repair with excision of the calcium
bar and creation of a new mitral annulus with autologous pericar-
dium.10
Since 1994, all patients with chronic atrial fibrillation had the
maze procedure at the time of mitral valve repair.11
Table 2 lists what leaflet was prolapsing and what operations
were performed.
Patients were anticoagulated with warfarin sodium during the
first 3 postoperative months if they were in sinus rhythm and
permanently if they were in atrial fibrillation.
Follow-up
Patients were followed by the referring cardiologist and contacted
by our research personnel every other year through a comprehen-
sive questionnaire. They were interviewed by telephone when the
cardiologist or the patient reported an adverse event. Echocardio-
grams were obtained yearly in most patients. Follow-up was ended
in December 2001. The mean follow-up time was 7.1 years (range,
3-19 years) for the entire group; it was 6.8  3.5 years for
asymptomatic and 7.3  3.8 for symptomatic patients. The fol-
low-up was complete.
Statistical Analysis
All data analyses were performed with SAS 8.1 software (SAS
Institute, Cary, NC). Descriptive statistics are reported as the
mean  SD for continuous variables and as frequencies and
percentages for categoric variables unless otherwise noted. Com-
parisons between the asymptomatic and symptomatic groups were
made with unpaired t tests for continuous variables and 2 or
Fisher exact tests for categoric variables. Estimates for long-term
survival or freedom from morbid events were made by using the
Kaplan-Meier method. The difference between survival curves
was evaluated by using the log-rank statistic. Age- and sex-
matched Ontario survival estimates were obtained from the Life
Table Template V1.2, a downloadable Excel spreadsheet devel-
oped by the Central East Health Information Partnership and
available at its Web site (http://www.cehip.org).
All preoperative candidate variables were entered into Cox
regression analyses to determine the independent multivariable
predictors of late outcomes. The appropriateness of variable trans-
formations was determined by means of univariate analysis. Vari-
ables with a univariate P value of less than .25 or those with known
biologic significance but failing to meet this critical  level were
submitted to the multivariable model. Criterion for retention of
variables in the model was set at a P value of .05. The following
variables were submitted to all multivariable models: age by
5-year increments, sex, NYHA functional class, left ventricular
grade, preoperative atrial fibrillation, preoperative stroke or tran-
sient ischemic attack (TIA), previous heart surgery, coronary ar-
tery disease, congestive heart failure, urgent-emergency surgery,
ascending aortic aneurysm, concomitant aortic valve surgery, hy-
pertension, diabetes, and chronic obstructive lung disease. The
adjusted risk ratios for the independent predictors and their 95%
confidence intervals are presented in the tables.
TABLE 2. Operative data
All patients Asymptomatic Symptomatic
Mitral valve prolapse
Posterior leaflet 238 (49) 103 (52) 135 (47)
Anterior leaflet 73 (15) 30 (15) 43 (15)
Bileaflet 177 (36) 66 (33) 111 (38)
Mitral valve repair
Partial resection of posterior leaflet 415 (85) 169 (85) 246 (85)
Chordal replacement with PTFE* 289 (69) 115 (58) 174 (60)
Chordal shortening 63 (14) 19 (9) 44 (15)
Chordal transfer 12 (3) 0 12 (4)
Annuloplasty 439 (90) 173 (87) 266 (92)
Mitral annulus reconstruction 11 (2) 2 (1) 9 (3)
Aortic valve repair 21 (5) 11 (5) 7 (2)
Aortic valve replacement 17 (4) 5 (2) 12 (4)
Replacement of ascending aorta/sinuses 13 (3) 8 (4) 5 (2)
Tricuspid valve repair 15 (3) 2 (1) 13 (4)
Coronary artery bypass 81 (17) 22 (11) 59 (20)
Maze procedure 23 (5) 4 (2) 19 (7)
Septal myectomy 5 (1) 2 (1) 3 (1)
Percentages are shown in parentheses.
*Gore-Tex, registered trademark of W.L. Gore & Associates, Inc, Flagstaff, Ariz.
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The Cox models were validated by using bootstrap methodol-
ogy. Two hundred random data sets of 400 patients each were
drawn from the original data set. The Cox model was rerun in each
data set. The frequency with which the variable remained in the
models was considered an indicator of the importance of the
variable as an independent predictor of outcome. A variable was
rejected if it did not occur in at least 50% of the models. In
addition, the risk ratios were averaged across the 200 models to
indicate the validity of the magnitude of the association.
Results
The 2 groups of patients in this study had different clinical
profiles, as seen in Table 1. Particularly important is the fact
that symptomatic patients were older, had higher rates of
chronic atrial fibrillation, had worse left ventricular func-
tion, and had a higher incidence of coronary artery disease
than asymptomatic patients.
Patient Survival
There were 5 operative deaths and 73 late deaths, as listed
in Table 3. Asymptomatic patients had significantly fewer
cardiac and valve-related deaths than symptomatic patients
(P  .001). A stepwise logistic regression analysis identi-
fied age by increments of 5 years, NYHA functional classes
3 and 4, impaired left ventricular function, preoperative
stroke or TIA, previous cardiac surgery, and chronic ob-
structive pulmonary disease as independent predictors of
late mortality, as shown in Table 4. Bootstrap validation of
these variables is also shown in Table 4.
Table 5 shows the Kaplan-Meier estimates of freedom
from valve-related, cardiac-related, and other causes of
death in the 2 groups of patients. Age by increments of 5
years, atrial fibrillation, and hypertension were independent
predictors of valve-related death. Table 6 shows the risk
ratio for these variables with bootstrap validation.
Figure 1 shows survival of all patients in comparison
with that of the general population matched for age and sex.
Figure 2 shows the survival of the 2 groups of patients and
the general population of Ontario matched for age and sex.
Asymptomatic patients had the same survival as the general
population of Ontario, whereas symptomatic patients had
significantly lower survival.
Valve-Related Complications
Thromboembolic complications occurred in 50 patients: 20
had TIA, and 30 had stroke.
Seven patients had infective endocarditis: 3 underwent
mitral valve replacement, 1 underwent rerepair, and 3 were
treated with antibiotics alone. All patients survived.
A total of 104 patients were taking coumadin at the time
of the last follow-up contact because of atrial fibrillation, a
postoperative thromboembolic event, or both. Major bleed-
ing related to anticoagulation occurred in 9 patients, and it
was fatal in 2 patients.
Twenty-three patients who had the maze procedure were
alive at the last follow-up contact; 19 were in sinus rhythm,
2 had atrioventricular paced beats, and 1 was in atrial
fibrillation. None of these patients had a postoperative
thromboembolic event.
Mitral valve reoperation was performed in 22 patients: 3
for dehiscence of the annuloplasty ring, 3 for hemolysis, 2
for mitral stenosis caused by pannus, 4 for endocarditis, 1
for a left ventricular coronary sinus fistula, and 9 because of
recurrent MR caused by chordal elongation or rupture. All
patients survived reoperation. The mitral valve was rere-
paired in 7 and replaced in 15 patients. Figure 3 shows the
freedom from reoperation in asymptomatic and symptom-
atic patients.
Eleven patients had severe MR: 10 were successfully
reoperated on, and 1 was deemed inoperable and died in
congestive heart failure. Sixty-six patients had moderate
MR, as determined by means of echocardiography, during
the follow-up period. Figure 4 shows the freedom of MR of
greater than 2 in asymptomatic and symptomatic patients.
Table 7 shows the Kaplan-Meier estimates of freedom
from various morbid events at 5, 10, and 15 years postop-
eratively.
There were no predictors of reoperation, thromboem-
bolic events, or recurrent MR by means of a stepwise
logistic regression analysis.
Although the rates of valve-related complications were
lower in asymptomatic than in symptomatic patients, the
differences between the 2 groups did not reach statistical
significance.
Late Functional Class
At the last follow-up, 137 (76%) patients in the asymptom-
atic group were in NYHA class 1, 31 (17%) were in class 2,
TABLE 3. Causes of death
Asymptomatic Symptomatic
Operative deaths
Dehiscence of aortic homograft 1
Myocardial infarction 2
Hemorrhagic stroke 1
Intestinal volvulus with peritonitis 1
Late deaths
Valve related
Anticoagulation-related bleeding 5
CHF caused by MR 1
Stroke 1 6
Cardiac related
CHF 8
Sudden 1 5
Myocardial infarction 1 4
Aortic valve replacement 0 1
Nonvalvular, noncardiac 7 33
CHF, Congestive heart failure.
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and 12 (7%) were in class 3. In the symptomatic group, 129
(60%) were in class 1, 39 (28%) were in class 2, 24 (11%)
were in class 3, and 2 were in class 4. One patient was
scheduled for mitral valve reoperation for late mitral steno-
sis.
Discussion
Most clinical investigators believe that mitral valve repair
results in a higher long-term survival than mitral valve
replacement in patients with mitral valve prolapse.12 Our
study indicates that late survival after mitral valve repair
depends on various factors, and in fact, the overall survival
is lower than that of the general population matched for sex
and age. Asymptomatic patients with severe MR caused by
floppy valves had identical long-term survival as the general
population matched for age and sex, whereas symptomatic
patients had significantly lower survival when compared
with the general population. Thus surgical intervention is
indicated in asymptomatic patients with severe MR if pre-
operative multiplane echocardiography indicates that the
mitral valve is repairable and operations can be performed
with low operative mortality and morbidity. Preoperative
echocardiography, particularly transesophageal echocardi-
ography, is currently the best diagnostic tool to determine
the ability for mitral valve repair.13 We believe that mitral
valve repair is feasible in all patients with single or bileaflet
prolapse as long as the leaflets are not excessively thickened
and the mitral annulus, the chordae tendineae, and the
papillary muscles are not calcified.
In addition to the severity of symptoms, left ventricular
ejection fraction of less than 40%, preoperative stroke or
TIA, previous cardiac surgery, and severe chronic obstruc-
tive pulmonary disease were also found to be predictors of
late mortality in our study. We had expected to find that
Figure 1. Survival after mitral valve repair in comparison with that
in the general population matched for age and sex, as depicted by
the dashed line.
TABLE 5. Kaplan-Meier estimates of freedom from valve-
related deaths, cardiac deaths, and other deaths
Freedom from: 5 y 10 y 15 y P value*
Valve-related death
NYHA 1-2 100 100 92 2 .008
NYHA 3-4 97 1 94 3 86 5
Cardiac death
NYHA 1-2 99 1 99 1 89 9 .005
NYHA 3-4 97 1 92 2 88 4
Other death
NYHA 1-2 98 1 93 3 93 3 .016
NYHA 3-4 97 1 85 3 72 7
*Kaplan-Meier P value.
TABLE 6. Predictors of valve-related death by means of Cox
regression analysis with bootstrap validation
RR (95% CI)
P
value
Bootstrap
validation
%
Average
d RR
Age/5 y 1.72 (1.2-2.5) .007 86 1.83
Preoperative arial
fibrillation/flutter
4.41 (1.2-16) .026 57 7.38
Hypertension 3.42 (1.1-10) .032 51 6.95
RR, Risk ratio; CI, confidence interval.
TABLE 4. Predictors of late mortality by means of Cox regression analysis with bootstrap validation
RR (95% CI) P value
Bootstrap validation
% Average d RR
Age/5 y 1.24 (1.1-1.4) .002 96 1.23
NYHA class 3 and 4 3.00 (1.3-6.8) .008 90 3.29
Ejection fraction 40% 2.68 (1.4-5.3) .004 89 3.16
Preoperative stroke/
TIA
3.15 (1.6-6.1) .001 94 3.25
Redo operation 4.61 (1.4-15) .012 63 5.16
COPD 3.13 (1.4-7.0) .005 76 3.56
Bootstrap validation is defined as 200 randomly selected sets of 400 patients each. Percentages are defined as frequencies with which the variable was
an independent predictor of the outcome. RR, Risk ratio; CI, confidence interval; COPD, chronic obstructive pulmonary disease.
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coronary artery disease was also a predictor of late death,
but this was not the case, as examined by means of Cox
regression analysis validated by using bootstrap methodol-
ogy. In previous studies on longitudinal outcomes of aortic
and mitral valve surgery from our institution, coronary
artery disease emerged as an important predictor of late
mortality.14,15 The presence of aortic or tricuspid valve
disease was not predictive of poor outcome either, although
only a small proportion of our patients had these associated
valve problems. It is possible that other noncardiac diseases
in addition to severe chronic obstructive pulmonary disease
might affect the long-term outcome if a larger sample size
had been analyzed.
Patients who have successful mitral valve repair for
floppy mitral valve disease continue to be exposed to risks
of cardiac and valve-related complications. Sudden death
and congestive heart failure are common among patients
with floppy mitral valves; correction of the MR decreases
the risk of these complications, but it does not abolish them
completely.16,17 Grigioni and associates16 found that sudden
death was relatively common in patients with MR caused by
mitral valve prolapse. NYHA functional class, left ventric-
ular ejection fraction, and atrial fibrillation were found to be
independent predictors of sudden death by those investiga-
tors.16 Surgical correction of the MR reduced the risk, but it
did not eliminate it. In our series of mitral valve repair, 6 of
20 cardiac deaths were sudden deaths, and one of them
occurred in the asymptomatic group.
Congestive heart failure after surgical correction of MR
is associated with poor long-term prognosis.17 The reason
for heart failure is often poor postoperative left ventricular
function, and it reinforces the notion that mitral valve sur-
gery should be performed before left ventricular systolic
function deteriorates.5,17,18 In our series of mitral valve
repair, there were 8 late deaths caused by congestive heart
failure, and 6 occurred among patients who had decreased
left ventricular ejection fractions preoperatively. All of
them were in the symptomatic group.
Stroke and TIA are relatively common in patients with
mitral valve prolapse, but these patients often have other
causes for cerebral ischemia.19,20 We could not establish the
reason why preoperative stroke or TIA was predictive of
late mortality in our series. Only 31 patients had experi-
Figure 2. Survival after mitral valve repair in asymptomatic and
symptomatic patients in comparison with that in the general
population matched for age and sex, as depicted by the thinner
lines.
Figure 3. Freedom from reoperation in asymptomatic and symp-
tomatic patients.
Figure 4. Freedom from MR of greater than 2.
TABLE 7. Kaplan-Meier estimates of freedom from morbid
events in all patients
Freedom from: 5 y 10 y 15 y
Valve-related death 98 1 95 1 89 4
Cardiac death 98 1 95 1 89 4
Other death 97 1 88 2 79 5
Reoperation 96 1 93 2 91 4
Thromboembolism 93 1 87 2 76 6
Endocarditis 99 1 98 1 98 1
Major bleeding 99 1 98 1 93 4
Valve-related mortality-morbidity 89 1 78 2 61 6
Recurrent MR (2) 99 1 94 2 85 7
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enced this complication preoperatively, and the high mor-
tality among them might have been by chance alone. Pa-
tients with floppy mitral valves have a constant risk of
stroke or TIA after mitral valve repair, as described in this
study and in others.12,21
Atrial fibrillation increases the risk of thromboembolism,
as well as the risk of hemorrhage, because these patients are
taking oral anticoagulants. Atrial fibrillation was identified
as an independent predictor of valve-related death in this
series, but it had no effect on overall survival. Since 1994,
we have combined the Cox-maze procedure with mitral
valve repair in patients in chronic atrial fibrillation.11 We
believe that it reduces the risk of thromboembolism and the
need for oral anticoagulation.11 Our experience is still too
small to determine its effect on valve-related deaths.
The risk of infective endocarditis in patients with mitral
valve prolapse and MR is probably reduced but not abol-
ished after mitral valve repair. Seven patients in our series
had endocarditis, and 4 required mitral valve replacement.
Although floppy mitral valve disease is a degenerative
disorder that is likely progressive, the long-term durability
of mitral valve repair has been excellent.12,21,22 The freedom
from reoperation at 15 years was 91% in our series. Other
investigators reported similar results.22 It has been pointed
out that the durability of repair of posterior leaflet prolapse
is better than that of anterior leaflet prolapse,12,21,22 but this
has probably changed since the introduction of newer op-
erative techniques to repair prolapse of the anterior leaflet.23
Indeed, we could not identify any predictor of recurrent MR
or reoperation in our present series, and the results with
isolated prolapse of the posterior leaflet were similar to
those of anterior or bileaflet prolapse. We believe that the
use of ePTFE sutures to replace elongated or ruptured
chordae tendineae has made a major difference in increasing
the probability of mitral valve repair in patients with ante-
rior leaflet and bileaflet prolapse, as well as increasing the
durability of the repair.7,23 Several investigators have shown
that chordal transfer is better than chordal shortening24 and
that chordal replacement with ePTFE is better than chordal
shortening.25 Since we introduced ePTFE sutures to replace
chordae tendineae in our practice, we have slowly aban-
doned both chordal shortening and chordal transfer in favor
of chordal replacement. Although we have had recurrent
MR in patients who had chordal replacement with ePTFE
sutures, the cause of recurrent MR was unrelated to the
synthetic chordae.
Although most surgeons agree that an annuloplasty ring
or posterior band is needed in patients with floppy mitral
valves, its value has been questioned repeatedly.26,27 We
believe that annular reduction is an important part of mitral
valve repair for floppy valve disease because the fibrous
annulus is often involved in the degenerative process, is
always dilated, and is sometimes posteriorly displaced
along its attachment with the left ventricle.28 These abnor-
malities must be corrected to obtain a durable repair.
This is a retrospective study of a clinical experience of a
single surgeon, and the results might not be generalizable.
The prevalence of associated cardiac and noncardiac dis-
eases was relatively small in this series, and statistical
values of certain variables might have been altered by
chance alone.
In conclusion, surgical intervention should be considered
in asymptomatic patients with severe MR caused by floppy
valves if valve repair is feasible, and it can be done with low
operative mortality and morbidity because the late survival
is identical to that of the general population. The durability
of mitral valve repair for floppy valves is excellent, but
valve- and cardiac-related complications in these patients
are not entirely abolished with surgical intervention.
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Discussion
Dr Michael A. Acker (Philadelphia, Pa). I congratulate Dr
David for this impressive series. This article represents the results
of 17 years of experience repairing myxomatous mitral valve
disease by a master surgeon. He has found, as Carpentier, Cos-
grove, and others have, that the vast majority of even the most
complex valve disorders can be repaired, and the repair is ex-
tremely durable, with an average reoperation rate of approximately
0.7% per year out to 15 years.
The results indicate that patients who are asymptomatic at the
time of surgery have a lower operative mortality, fewer late cardiac
deaths, and a normal life expectancy when compared with matched
control subjects, which is in marked contrast to patients with
symptoms at the time of surgical intervention. It is important,
however, to note that symptoms per se were not predictive of late
mortality. Rather the independent predictors were severe symp-
toms, such as class III or class IV heart failure, decreased left
ventricular function with an ejection fraction of less than 40%, and
increased age.
Dr David justifiably concludes that in his hands even the patient
who is completely asymptomatic (ie, class I or 0) and who is
judged to have a repairable valve should undergo mitral valve
repair. American College of Cardiology and American Heart As-
sociation guidelines already strongly endorse a class I indication
for mitral valve repair in patients with mild symptoms and a class
II indication, or patients who are totally asymptomatic if the
ejection fraction is less than 60% and end-systolic diameter is
greater than 45 mm. The recommendations for surgical interven-
tion for the completely asymptomatic patient with severe MR who
has normal left ventricular function and size, an ejection fraction of
greater than 60%, and an end-diastolic dimension less than 45 mm
is more equivocal, and they have it presently as a class IIb
recommendation.
I have several questions. Because it is impossible to predict
how long the truly asymptomatic patient with normal left ventric-
ular function and size and severe MR will remain in this state and
because there will always be a small but present operative mor-
tality, such as there was in your study, would it not be better to
have a strategy to follow echocardiographically these types of
asymptomatic patients with normal left ventricular function and
wait for the development of either very mild symptoms, a slight
decrease in systolic function (eg, 60%), or an increase in left
ventricular end-systolic dimensions (eg, 45 mm)?
How often after complex bileaflet repair was there mild-to-
moderate residual MR (ie, 1 to 2)? Did 1 to 2 residual MR
predict a later need for reoperation or the development of more
severe MR? Do you presently accept 1 to 2 MR after a complex
bileaflet mitral valve repair?
As a follow-up of your earlier discussion of the first article,
presently in an elderly patient greater than 65 years old with
complex bileaflet disease and the need for extensive bileaflet
procedures, do you think that patient would be equally served by
mitral valve replacement with a bioprosthetic valve if the sub-
chordal apparatus is to be completely retained?
Finally, obviously the key decision before recommending sur-
gical intervention for the asymptomatic patient with normal left
ventricular function is the likelihood of repair. With that in mind,
can you comment on what the specific echocardiographic charac-
teristics and diseases are that make you decide a valve is not
repairable? Are these the same echocardiographic characteristics
and diseases you would recommend a surgeon without your ex-
tensive experience and skill to shy away from or to monitor the
patient further? How often did you attempt repair but fail and need
to replace the valve? Finally, do you believe that your general
recommendation for valve repair in asymptomatic patients with
normal left ventricular function is generalizable to most cardiac
surgeons and environments?
Dr David. Thank you, Dr Acker. When we first looked at these
data, the first question that came to our minds was why we had
operated on 55 patients without symptoms back in the 1980s. The
answer was that most of them had impairment of left ventricular
function, an enlarged left atrium, or an aortic root aneurysm. Our
approach has changed, however, since we reviewed our experi-
ence. In the past 2 or 3 years, we have been offering surgical
intervention to patients without symptoms and normal cardiac
dimensions and systolic and diastolic function, which takes me to
your fourth question, if I might answer it now.
In patients with severe MR and no symptoms, we obtain a
transesophageal echocardiogram to take a close look at the mor-
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phology and mechanism of mitral valve prolapse. If it is due to
a single leaflet prolapse, we tell patients that the likelihood of
repair is near 100%. It does not matter whether it is the anterior
or the posterior leaflet. Since the introduction of polytetrafluo-
roethylene sutures to replace chordae tendineae, there is no
leaflet prolapse that cannot be repaired. We have a 16-year
experience with chordal replacement in several hundred pa-
tients, and we have never reoperated because of failure of the
polytetrafluoroethylene chordae. For bileaflet prolapse with
normal leaflets of normal thickness, we also offer surgical
intervention. If the mitral annulus is larger than 60 mm, if the
leaflets are more than 3 to 4 mm in thickness with prolapse of
multiple segments, we do not offer surgical intervention and
wait until there is a hemodynamic indication, such as impair-
ment of systolic function or symptoms.
We do not accept more than 1 MR after mitral valve repair,
even when a complex repair is done, such as in patients with
advanced myxomatous disease or a heavily calcified mitral annu-
lus. The area of the regurgitant jet has to be less than 2 or 3 cm2.
Perhaps even more important than the amount of MR is the
morphologic state of the mitral valve after repair. If the coaptation
of the leaflets is not inside the ventricle, I believe the patient should
go back on cardiopulmonary bypass and the valve should be
rerepaired because this is probably the best predictor of late failure.
Finally, the elderly or the patient who needs a complex repair
and has extensive coronary artery disease might be better served
by mitral valve replacement with preservation of the chordae
tendineae. Having said that, I would repair the mitral valve of an
85-year-old patient with triple-vessel disease if the mitral disease
is simple, such as prolapse of a single segment.
Are our results generalizable to all surgeons? Probably not. I
had my first lessons on mitral valve repair back in 1979 with Dr
Alain Carpentier. My very first repair failed, and I was very
disappointed because after watching Dr Carpentier operate, I
thought that there was nothing to mitral valve repair. It took me
another 6 months to be brave enough to repair the second case.
This one worked very well, and I did a third with equal success.
The fourth failed, but the next 10 did well, and I think by that time
I had passed the initial learning curve. Like anything else in life,
the more you practice, the better you get at it. Beginners should
start to repair simple valve disorders, such as prolapse of P2 or
rupture of a single chorda to the anterior leaflet, and then progres-
sively take on more complex cases.
Dr Alain F. Carpentier (Paris, France). I rise to congratulate
Tirone for this excellent presentation and for raising the question
of asymptomatic patients. First, I have a comment. It is hard for me
to understand when you are talking about a floppy mitral valve. Do
you mean only the Barlow syndrome, or do you incorporate all
types of degenerative valvular disease, including fibroelastic defi-
ciency?
Dr David. The entire spectrum of mitral valve prolapse caused
by degenerative disease is included, Professor Carpentier. In other
words, I include fibroelastic deficiency, Barlow syndrome, myxo-
matous degeneration, floppy mitral valve, those who have a seg-
ment that prolapsed because of rupture of the chordae tendineae,
elongation, or degenerative changes. Ischemic and rheumatic
causes are excluded.
Dr Carpentier. It would be nice to have a common agreement
separating the diseases from the dysfunction and talking about
prolapse when there is a dysfunction.
Dr David. Professor Carpentier, when I finished the course
with you, I returned home and told my cardiac pathologist that you
distinguished leaflet prolapse caused by fibroelastic deficiency
from myxomatous degeneration. His reply was that they were the
same disease. From that time on, I have referred to them as floppy
mitral valves.
Dr Carpentier. I would be delighted to have the address of
your pathologist and to challenge him on pathology. He is making
a confusion between a primary disease and a secondary relation
caused by the dysfunction.
Dr David. Professor Carpentier, let me add that I have used the
classification you taught me back in 1980, and less than 5% of my
patients have what you refer to as fibroelastic deficiency.
Dr Carpentier. Let us concentrate on the most important
aspect of your article. I really congratulate you on raising the
question of asymptomatic patients. I have a hard time convincing
our patients, even with the large experience we have, to undergo
surgical intervention if they are totally asymptomatic with normal
left ventricular function and normal left ventricular dimension
because we still have, let us say, even less than 0.4% operative
mortality. Everything can happen during surgical intervention, and
therefore it would be extremely difficult to justify and to advise
young surgeons to operate on totally asymptomatic patients,
whereas we can have some more sound data to tell them, “Okay,
we have to operate on you because you have an involuted process
with small, progressive enlargement of the left ventricle.”
Wouldn’t you agree with that policy?
Dr David. Yes, I would agree with your policy.
Dr Carpentier. Do not push too much, too far.
Dr David. However, there are a couple of studies on the natural
history of patients with mitral valve prolapse and no symptoms.
They have a risk of approximately 0.5% per year for sudden death
syndrome, 0.2% per year for endocarditis. If you add that over 10
years most if not all have symptoms, ventricular dysfunction, or
both, and then it makes sense to operate earlier.
Dr Carpentier. Your point is very well taken. However, this
group of patients having a sudden death belong to a very specific
pathology group that we have to discuss with your pathologist.
Anyway, my third and very brief question is the following. You
had a 15% incidence of residual moderate-to-severe residual in-
sufficiency after 15 years, which is good. However, as usual, I am
interested to know the causes of these recurrent or residual insuf-
ficiencies within this 15-year time frame.
Dr David. This was not residual but rather recurrent MR. We
started with a 98% freedom from moderate or severe MR by the
end of the first postoperative year. To be quite honest, I have 2
previous studies on longitudinal outcomes of mitral valve repair,
and in both of them I made inferences that the recurrence in the
first decade is largely the result of technical errors. Now I have to
add that even if you do a perfect job in the operating room, the
degenerative disease is progressive, and by 15 years, most of my
patients who had recurrent MR did so because of prolapse of
segments that were normal before.
Mr Magdi H. Yacoub (London, United Kingdom). I enjoyed
your presentation, Dr David. I have 2 very minor questions. First,
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what is your definition of asymptomatic? If a patient had a history
of heart failure, pulmonary edema, or both, or suddenly had
worsening in mitral valve disease, does that patient remain asymp-
tomatic if he was asymptomatic at the time of assessment? In the
same vein, would you consider using exercise capacity with gas
exchange, for example, to define your asymptomatic group? Sec-
ond, have you compared the severity of MR in your 2 groups by
some sort of an objective method, such as regurgitant fraction or
effective regurgitant orifice or one of these indices?
Dr David. I have a database on all patients operated on since
I started practicing. One of the entries is the NYHA functional
classification. In this study we identified as “asymptomatic” and
“minimally symptomatic” patients who were in functional classes
I and II, respectively. We did not exercise our asymptomatic
patients. I do not know the value of exercise tests in patients with
MR. We do that in asymptomatic patients with aortic insufficiency
before we recommend surgical intervention.
We quantitate MR by means of echocardiography. We call it
severe when there is a large jet and reversal of pulmonary venous
flow. Both groups of patients in this series had severe MR.
Dr Kevin D. Accola (Orlando, Fla). Thank you, Dr David, for
a very informative series.
As one of the younger surgeons to whom Professor Carpentier
alluded, from a technical standpoint, I noticed that in 8% to 10%
of your patients, you did not use an annuloplasty ring. Could you
describe your decision process in those patients? Did they subse-
quently reflect in any of your results requiring reoperation where
any of your patients came back with significant insufficiency?
Dr David. Recurrent MR was unrelated to the lack of an
annuloplasty ring. However, although some patients had no ring,
they had some sort of reduction annuloplasty. If the annulus was
already very small and only P2 was resected or if they had acute
chordal rupture caused by fibroelastic deficiency, no annuloplasty
ring was used. Patients with fibroelastic deficiency frequently have
a normal mitral annulus. I would like to hear Professor Carpenti-
er’s opinion on this.
We found no predictors of recurrent MR in this series. We
always use a ring in patients with myxomatous disease of the
mitral valve because the annulus is always dilated in these patients.
Maybe Professor Carpentier can make a comment about the need
for a ring in patients with fibroelastic deficiency.
Dr Carpentier. I enjoyed very much that you differentiated
between fibroelastic deficiency and Barlow syndrome despite your
pathologist. They are 2 different diseases. You are absolutely right.
Now, it is true that in fibroelastic deficiency you have a type II
P2 caused by one single ruptured chord, and the rest of the valve
seems to be normal. The problem is that the fibroelastic deficiency
involves not only the leaflet and the chordae but also the whole
valvular apparatus. Placing a ring takes an additional 15 minutes,
and this is the price to pay to have a long-lasting repair and
stabilization of the annulus for the rest of the life of the patient
because our aim today is no longer to correct the mitral valve
deficiency but to provide a lifelong cure.
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